Claims for Patent: 5,777,193

Summary for Patent: 5,777,193

Title:	Animals with targeted gene disruption
Abstract:	The invention provides transgenic non-human animals in which genes encoding colony-stimulating factors have been specifically disrupted, so that the animals do not express the respective factors. In specific embodiments the invention provides mice in which expression of GM-CSF, G-CSF and/or CSF-1 is disrupted. These animals do not produce any bioactive CSF of the respective type. They are useful as models for a variety of conditions, and particularly for testing of therapeutic methods.
Inventor(s):	Dunn; Ashley Roger (Parkville, AU), Stanley; Edouard Guy (London, GB), Lieschke; Graham John (Parkville, AU), Grail; Dianne (Parkville, AU), Fowler; Kerry J. (Parkville, AU)
Assignee:	Ludwig Institute For Cancer Research (New York, NY)
Application Number:	08/211,651
Patent Claims:	1. A transgenic mouse comprising a homnozygous disruption of a gene encoding GM-CSF in its somatic and germ cells wherein said disruption results in an inability of said mouse to produce detectable levels of GM-CSF and further wherein said mouse has a lung disorder characterized by alveolar proteinosis. 2. A transgenic mouse comprising a homozygous disruption of a gene encoding G-CSF in its somatic and germ cells wherein said disruption results in an inability of said mouse to produce detectable levels of G-CSF and further wherein said mouse has neutropenia. 3. A compound homozygous transgenic mouse comprising homozygous disruptions in its somatic and germ cells in both the gene encoding GM-CSF and the gene encoding M-CSF, wherein said disruptions result in an inability of said compound homozygous transgenic mouse to produce detectable levels of GM-CSF and M-CSF, and further wherein said mouse has osteopetrosis. 4. A transgenic mouse according to claim 1, wherein said homozygous disruption of the gene encoding GM-CSF comprises deletion of exons 1 and 2 and intron 1 betweec Scal and Smal restriction sites of the gene encoding GM-CSF. 5. A transgenic mouse according to claim 2, wherein said homozygous disruption of the gene encoding G-CSF comprises a deletion from the Ncol site in exon 1 which encompasses the translation initiation codon ATG to the BamHl restriction site in exon 3 of the gene encoding G-CSF. 6. A method of testing the efficacy of a putative method of treatment of alveolar proteinosis comprising, subjectiig the transgenic mouse of claim 1 to said putative treatment, and determining whether said treatment is effective for treating alveolar proteinosis. 7. The method according to claim 6, wherein said putative treatment comprises the administration of a chemotherapeutic agent to said transgenic mouse. 8. A method according to claim 6, in which the putative treatment comprises administering a cytokine. 9. The method according to claim 8, wherein the cytokine is selected from the group consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) granulocyte- colony stimulating factor (G-CSF), colony-stimulating-factor-1 (CSF-1), leukemia inhibitory factor (LIF), and transforming growth factor -.beta.1 (TGF-.beta.1). 10. A method according to claim 7, wherein the chemotherapeutic agent is GM-CSF. 11. A method of testing the efficacy of a putative treatment for infectious disease comprising (a) exposing the mouse of claim 1 or 2 with an infectious agent at a level sufficient to cause disease symptoms in said mouse, (b) treating said mouse with said putative treatment and (c) determining whether said treatment prevents or reduces said disease symptoms. 12. A method according to claim 11, wherein said infectious disease is a bacterial, fungal or viral infection of the lung. 13. A method for testing a putative treatment for an infectious disease comprising: (a) treating the mouse of claim 1 with said putative treatment; (b) exposing the resultant treated mouse to an infectious agent at a level sufficient to cause disease symptoms in a mouse of claim 1 that has not been treated, and (c) determining whether said treatment prevents or reduces said disease symptoms. 14. A method for testing a putative treatment for an infectious disease comprising: (a) treating the mouse of claim 2 with said putative treatment; (b) exposing the resultant treated mouse to an infectious agent at a level sufficient to cause disease symptoms in a mouse of claim 2 that has not been treated; and, (c) determining whether said treatment prevents or reduces said disease symptoms. 15. A method according to claim 13 or 14, wherein said infectious disease is a bacterial, fungal or viral infection.

Details for Patent 5,777,193

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26